Ten years after the launch of a mobile outpatient cardiac telemetry device from medtech company BioTelemetry, Inc., insurer Health Care Service Corp. (HCSC) has included it in its medical coverage policy. Pennsylvania-based manufacturer BioTelemetry revealed the coverage decision in a February earnings call, saying that the move was the result of a non-stop effort to flip a small holdout of insurers. BioTelemetry says about 95% of payers cover the diagnostic device, and many without step therapy requirements that mandate patients try other devices first.
The mobile outpatient cardiac telemetry (MOCT) device is perhaps one of the most recent medical developments used for diagnosing heart rhythm and rate abnormalities. These problems — the heart pumping too slow or too fast — can cause sudden cardiac arrest, stroke and/or death.